$10.72
0.010.09%
Fennec Pharmaceuticals Inc
FENCNASDAQ
Fennec Pharmaceuticals (FENC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Fennec Pharmaceuticals (FENC) last issued guidance on February 29, 2024 for fiscal year 2023. The company guided revenue in the range of $20.7M - $21.2M for the period.
Compared to prior guidance, Fennec Pharmaceuticals raised its revenue forecast from a prior range of $9.2M - $9.7M.
Fennec Pharmaceuticals has issued 2 guidance updates between February 29, 2024 and February 29, 2024. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.02 | $-0.02 | $0.04 | $-0.05 |
| Actual | $0.05 | $0.01 | $-0.17 | $-0.02 |
| Surprise | +150.0% | +150.0% | -525.0% | +60.0% |
| Revenue | ||||
| Estimate | $16.1M | $13.9M | $14.8M | $11.2M |
| Actual | $17.9M | $15.1M | $13.8M | $12.5M |
| Surprise | +11.1% | +8.99% | -7.09% | +11.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.10 | $0.13 | $0.14 | $0.20 |
| Revenue | ||||
| Consensus | $18.9M | $20.7M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $0.05 | $0.02 | 150.0 % |
| Q1 | May 14, 2026 | $0.01 | $-0.02 | 150.0 % |
| Q4 | Mar 24, 2026 | $-0.17 | $0.04 | -525.0 % |
| Q3 | Nov 13, 2025 | $-0.02 | $-0.05 | 60.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $17.87M | $16.09M | 11.1 % |
| Q1 | May 14, 2026 | $15.11M | $13.86M | 8.99 % |
| Q4 | Mar 24, 2026 | $13.78M | $14.83M | -7.09 % |
| Q3 | Nov 13, 2025 | $12.46M | $11.22M | 11.1 % |
